Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2018; 9:17255.

The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo

Fei Shi, Jinying Zhang, Hongyu Liu, Liangliang Wu, Hongyu Jiang, Qiyan Wu, Tianyi Liu, Meiqing Lou and Hao Wu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:706-717. https://doi.org/10.18632/oncotarget.23091

Metrics: PDF 1543 views  |   HTML 2295 views  |   ?  


Abstract

Fei Shi1,*, Jinying Zhang2,*, Hongyu Liu3, Liangliang Wu3, Hongyu Jiang4, Qiyan Wu3, Tianyi Liu3, Meiqing Lou1,# and Hao Wu5,#

1Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200000, China

2Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, China

3Key Laboratory of Cancer Center, Chinese PLA General Hospital, Beijing 100853, China

4Department of Anesthesiology, Wuxi Third People’s Hospital, Wuxi, Jiangsu 214000, China

5Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

*These authors contributed equally to this work

#Co-senior authors

Correspondence to:

Hao Wu, email: [email protected]

Meiqing Lou, email: [email protected]

Keywords: chemotherapy; dactolisib (NVP-BEZ235); dual PI3K/mTOR inhibitor; glioblastoma; radiotherapy

Received: October 15, 2017     Accepted: December 01, 2017     Published: December 09, 2017

ABSTRACT

Glioblastomas (GBMs) are among the most malignant of all human tumors and have poor prognosis. The current standard of care (SOC) includes maximal surgical tumor resection followed by adjuvant temozolomide (TMZ) and concomitant radiotherapy (RT). However, even with this treatment, the 5-year survival rate is less than 10%, and thus, follow-up treatment is required to improve efficacy. In GBMs as well as many other solid cancers, PI3K/mTOR signaling is overactivated. Therefore, multiple tumor-based PI3K inhibitors have been studied in various cancers. In the current study, we investigated the effect of the dual PI3K/mTOR inhibitor dactolisib on TMZ+RT treatment in three human GBM cell lines and a orthotopic xenograft model. Dactolisib alone induced cytotoxicity and pro-apoptotic effects, which act as antitumor factors. Combined with SOC treatment, dactolisib inhibited cell viability, induced enhanced pro-apoptotic effect, and attenuated migration/invasion in all three cell lines, thereby enhancing the SOC therapeutic effect. Protein microarray analysis showed that A172 cells treated with TMZ+RT+dactolisib had higher p27 and lower Bcl-2 expression than other groups. Moreover, in the xenograft model, oral dactolisib combined with TMZ+RT inhibited tumor growth and prolonged survival. Thus, SOC combined with dactolisib shows potent anti-tumor activity and has promising potential for solid tumor treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23091